Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the publication of 3 abstracts for poster presentations at the ...

Radiant Biotherapeutics, a preclinical biotechnology company developing an antibody platform to deliver first-in-class transformative therapies for patients facing life-changing disease, today ...

What if business leaders approached strategy the way scientists design gene delivery vectors? In biotechnology, precision, ...

A scientific revolution is underway as researchers push to bring atomic-level precision, once reserved for small molecule ...

Transgene Provides Business and Financial Update for Q1 2025  TG4050: Updated randomized Phase I data to be presented in Rapid Oral Presentation at ASCO 2025Dr. Simone Steiner appointed Chief ...

BioAtla (BCAB) announced preclinical poster presentations at the upcoming 2025 American Association for Cancer Research to be held at the ...

A copy of the presentation materials can be accessed on the “ Publication ” section of the Company’s website at www.bioatla.com once the presentations have concluded.

Nobel laureate David Baker, right, speaks with BioCentury's Simone Fishburn at the Life Science Innovation Northwest ...

Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, will present the ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with ...

The company will also present a poster on randomized Phase II data of TG4001 in combination with avelumab in the cervical cancer subgroup. The 2025 American Society of Clinical Oncology (ASCO), annual ...

Chemomab Therapeutics, Ltd ., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that ...